심부전 치료제 시장 : 약제 클래스별, 심부전 유형, 투여 경로, 작용기전, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Heart Failure Therapeutics Market is projected to grow by USD 60.23 billion at a CAGR of 10.94% by 2032.

Heart Failure Therapeutics Market Introduction

Heart failure therapeutics remain central to cardiovascular care because heart failure affects more than 64 million people worldwide, while cardiovascular diseases cause an estimated 17.9 million deaths each year, according to the World Health Organization. The heart failure treatment landscape is shifting from episodic symptom control toward guideline-directed medical therapy that lowers mortality, reduces hospitalization, improves functional status, and slows disease progression across reduced, mildly reduced, and preserved ejection fraction.

Demand for evidence-based heart failure drugs is reinforced by aging populations, diabetes, obesity, hypertension, chronic kidney disease, and improved survival after myocardial infarction. Clinicians are increasingly using angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, diuretics, iron repletion, and device-enabled care in integrated pathways designed to improve outcomes and support long-term disease management.

Transformative Shifts in the Heart Failure Landscape

The heart failure therapeutics landscape is being reshaped by the rapid adoption of four-pillar treatment for heart failure with reduced ejection fraction, wider use of SGLT2 inhibitors across ejection-fraction categories, and earlier initiation of combination therapy after diagnosis or hospital discharge. Major guidelines from the AHA, ACC, HFSA, and ESC emphasize faster optimization of evidence-based medicines rather than slow sequential escalation, reflecting clinical trial evidence that timely treatment reduces cardiovascular death and heart failure hospitalization.

Commercial strategy is also changing. Payers increasingly evaluate heart failure therapies by their ability to reduce hospital admissions, improve quality of life, support outpatient management, and lower avoidable acute-care use. At the same time, patent expirations, generic availability, fixed-dose combinations, remote patient monitoring, and multidisciplinary care models are changing access, pricing, adherence, and differentiation across the heart failure drug market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler in heart failure therapeutics rather than a standalone treatment. Validated AI tools are being applied to electrocardiogram interpretation, echocardiography workflows, risk stratification, patient identification, medication adherence support, and prediction of clinical decompensation using electronic health records, imaging, laboratory results, wearable devices, and remote monitoring data.

The cumulative impact is strongest where AI improves earlier diagnosis, therapy titration, clinical trial recruitment, population health management, and pharmacovigilance. However, adoption depends on transparent validation, demographic fairness, cybersecurity, clinician oversight, and regulatory alignment. For drug developers and healthcare decision-makers, AI-enabled real-world evidence can strengthen market access dossiers, identify underdiagnosed patients, and support selection of patients most likely to benefit from specific heart failure therapies.

Key Regional Insights Across Heart Failure Therapeutics

Asia-Pacific is a highly dynamic heart failure therapeutics region due to large aging populations, rising diabetes prevalence, urbanization, and expanding cardiology infrastructure across China, India, Japan, Australia, and South Korea. North America remains a leading innovation and adoption hub, supported by AHA/ACC/HFSA guideline implementation, specialist heart failure programs, clinical trial density, advanced diagnostics, and comparatively strong reimbursement for branded therapies, outpatient care models, and digital health integration.

Latin America shows increasing demand for heart failure treatment but faces uneven access to advanced medicines, diagnostics, and specialist services, with Brazil and Mexico acting as key regional anchors. Europe benefits from ESC-led standardization, national health technology assessment systems, broad use of evidence-based therapy, and structured pharmacovigilance, although cost-effectiveness scrutiny is significant. The Middle East is expanding cardiovascular investment as diabetes, hypertension, and obesity burden rises, while Africa remains underpenetrated, with affordability, diagnosis rates, workforce capacity, and supply continuity shaping therapeutic uptake.

Key Group Insights for Strategic Market Positioning

ASEAN markets are gaining relevance as hospital networks expand and governments strengthen noncommunicable disease programs, though access to newer heart failure medicines varies by reimbursement, public procurement, and urban-rural capacity. The GCC is strategically important because high rates of diabetes, hypertension, obesity, and chronic kidney disease create sustained demand for cardiometabolic and heart failure care, supported by healthcare modernization programs, specialty centers, and investment in digital health infrastructure.

The European Union provides regulatory scale, pharmacovigilance infrastructure, and health technology assessment-driven pricing discipline, making clinical value and budget impact central to access. BRICS countries combine large patient pools with rising domestic manufacturing, expanding insurance coverage, and cost-sensitive procurement, making affordability, local evidence, and supply reliability essential. G7 markets lead in clinical innovation, premium therapy adoption, and real-world evidence generation. NATO members, while not a healthcare bloc, overlap with major high-income markets where supply-chain resilience, essential medicines security, and health-system readiness are increasingly strategic priorities.

Key Country Insights in Major Heart Failure Markets

The United States is the most commercially influential heart failure therapeutics market, supported by high disease burden, advanced specialty care, broad clinical trial participation, and rapid incorporation of guideline-directed medical therapy; Canada follows similar clinical standards with stronger centralized cost-effectiveness review and provincial reimbursement influence. Mexico and Brazil are important Latin American markets where public access, private insurance penetration, local procurement, and specialist availability determine uptake of advanced heart failure medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature cardiology systems with pricing oversight, national reimbursement rules, and guideline-based care pathways, while Russia presents a large patient base with access, procurement, and geopolitical constraints. China and India drive Asia-Pacific patient volume, supported by expanding diagnosis, domestic manufacturing, hospital capacity, and policy attention to chronic disease management. Japan, Australia, and South Korea are advanced markets with strong regulatory standards, aging populations, high-quality cardiovascular care, and growing interest in integrated drug-device-digital heart failure management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and programs that demonstrably reduce hospitalization, cardiovascular mortality, symptom burden, and total cost of care. Portfolio strategies should align with guideline-directed medical therapy, support rapid titration, and address common comorbidities such as chronic kidney disease, diabetes, iron deficiency, hypertension, atrial fibrillation, and obesity.

Manufacturers should expand real-world evidence, pursue inclusive clinical trials, strengthen payer-ready economic models, and invest in patient support that improves treatment persistence and adherence. Regional strategies must balance premium innovation with affordability through tiered pricing, local partnerships, supply security, physician education, and care pathway support for primary care and cardiology teams. AI-enabled identification, remote monitoring integration, decentralized follow-up, and outcomes-based contracting can further improve differentiation in heart failure therapeutics.

Research Methodology

The research methodology is built on secondary research from verified public and scientific sources, including global health agencies, cardiology guidelines, regulatory labels, peer-reviewed clinical trials, health technology assessment frameworks, epidemiology databases, and disease burden publications. Priority was given to evidence from the World Health Organization, AHA/ACC/HFSA, ESC, national regulatory authorities, and landmark randomized heart failure trials evaluating mortality, hospitalization, safety, and quality-of-life outcomes.

Insights were triangulated across disease burden, treatment standards, regulatory status, reimbursement dynamics, clinical adoption, access barriers, comorbidity patterns, and regional healthcare capacity. The analysis avoids unsupported market-size claims and focuses on evidence-backed therapeutic, geographic, and strategic signals relevant to heart failure drug developers, investors, payers, providers, and healthcare decision-makers.

Conclusion

Heart failure therapeutics are entering a more outcomes-driven phase defined by earlier diagnosis, faster initiation of combination therapy, broader SGLT2 inhibitor use, stronger comorbidity management, and deeper integration of digital and AI-enabled care. The competitive landscape rewards therapies that improve survival, reduce hospitalization, simplify care pathways, enhance adherence, and prove value in real-world heart failure populations.

Growth opportunities are strongest where clinical innovation is paired with access strategy and implementation support. Organizations that combine robust evidence, regional affordability, payer engagement, supply reliability, and technology-enabled patient management will be best positioned to meet rising demand across mature and emerging heart failure therapeutics markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Heart Failure Therapeutics Market, by Drug Class

• 7.1. ACE Inhibitors
• 7.2. Angiotensin II Receptor Blockers
• 7.3. Beta Blockers
• 7.4. Diuretics
• 7.5. Mineralocorticoid Receptor Antagonists
• 7.6. SGLT2 Inhibitors

8. Heart Failure Therapeutics Market, by Heart Failure Type

• 8.1. Preserved Ejection Fraction
• 8.2. Reduced Ejection Fraction
• 8.3. Heart Failure with Mildly Reduced EF

9. Heart Failure Therapeutics Market, by Mode Of Administration

• 9.1. Intravenous
• 9.2. Oral

10. Heart Failure Therapeutics Market, by Mechanism of Action

• 10.1. Neurohormonal Modulation
• 10.2. Vasodilation
• 10.3. Positive Inotropy
• 10.4. Metabolic Modulation

11. Heart Failure Therapeutics Market, by End User

• 11.1. Clinics
• 11.2. Home Care Settings
• 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

• 12.1. Offline
  • 12.1.1. Hospital Pharmacies
  • 12.1.2. Retail Pharmacies
• 12.2. Online

13. Heart Failure Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Heart Failure Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Abiomed, Inc.
• 17.3. Amgen Inc.
• 17.4. AstraZeneca PLC
• 17.5. Bayer AG
• 17.6. BioCardia, Inc.
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Boston Scientific Corporation
• 17.9. Bristol-Myers Squibb Company
• 17.10. CVRx, Inc.
• 17.11. Cytokinetics, Inc.
• 17.12. Edwards Lifesciences Corporation
• 17.13. Eli Lilly and Company
• 17.14. GlaxoSmithKline plc
• 17.15. Hikma Pharmaceuticals PLC
• 17.16. Johnson & Johnson Services, Inc.
• 17.17. Les Laboratoires Servier
• 17.18. Medtronic plc
• 17.19. Merck & Co., Inc.
• 17.20. Novartis AG
• 17.21. Orion Corporation
• 17.22. Pfizer Inc.
• 17.23. PhaseBio Pharmaceuticals, Inc.
• 17.24. Renova Therapeutics, Inc.
• 17.25. Sanofi S.A.
• 17.26. Takeda Pharmaceutical Company Limited